

1. An antineoplastic composition comprising an inhibitor of angiogenesis and an inhibitor of DNA topoisomerase I enzyme activity.

2. The antineoplastic composition of claim 1, wherein said inhibitor of angiogenesis is a
5 thrombospondin compound.

3. The antineoplastic composition of claim 1, wherein said inhibitor of DNA topoisomerase I enzyme activity is a camptothecin compound.

10 4. The antineoplastic composition of claim 2, wherein said thrombospondin compound is thrombospondin-1.

5. The antineoplastic composition of claim 2, wherein said thrombospondin compound is thrombospondin-2.

6. The antineoplastic composition of claim 3, wherein said camptothecin compound is irinotecan (CPT-11).

7. The antineoplastic composition of claim 3, wherein said camptothecin compound is topotecan.

8. The antineoplastic composition of claim 3, wherein said camptothecin compound is selected from the group consisting of 20-S-camptothecin (20(S)CPT), 10,11-methylenedioxy-CPT (10,11-CPT), 7-ethyl-10-hydroxy-CPT (SN38), and 9-AC³.

9. A method of inhibiting tumor cell growth in a mammal, comprising administering to said mammal a composition comprising an inhibitor of angiogenesis and an inhibitor of DNA topoisomerase I enzyme activity.

30 10. The method of claim 9, wherein said inhibitor of angiogenesis is a thrombospondin compound.

Sub
B2

11. The method of claim 9, wherein said inhibitor of DNA topoisomerase I enzyme activity is a camptothecin compound.

5 12. The method of claim 10, wherein said thrombospondin compound is thrombospondin-1.

13. The method of claim 10, wherein said thrombospondin compound is thrombospondin-2.

10 14. The method of claim 11, wherein said camptothecin compound is irinotecan (CPT-11).

15. The method of claim 11, wherein said camptothecin compound is topotecan.

15 16. The method of claim 11, wherein said camptothecin compound is selected from the group consisting of 20-S-camptothecin (20(S)CPT), 10,11-methylenedioxy-CPT (10,11-CPT), 7-ethyl-10-hydroxy-CPT (SN38), and 9-AC³.

20 17. The method of claim 9, wherein said mammal is a human.

18. The method of claim 9, wherein said inhibitor of angiogenesis is administered prior to said inhibitor of DNA topoisomerase I enzyme activity.

Sub
B3

25 19. The method of claim 9, wherein said inhibitor of DNA topoisomerase I enzyme activity is administered prior to said inhibitor of angiogenesis.

20. The method of claim 9, wherein said inhibitor of angiogenesis and said inhibitor of DNA topoisomerase I enzyme activity are administered simultaneously.